Methods	Randomised, double blind, parallel group, partial enriched enrolment. 1-week fixed titration (8 weeks in total)
Participants	Painful postherpetic neuralgia 6 months after healing of herpes zoster skin rash and pain of at least 40/100 mm or numerical rating of at least 4/11 at baseline. Mean age 72 years, 45% female, 99% white
Interventions	Pregabalin 150 mg daily, n = 81 Pregabalin 300 mg daily, n = 76 Placebo daily, n = 81
Outcomes	Proportion of patients with ≥ 50% decrease in mean pain score between endpoint and baseline, and other outcomes
Notes	Oxford quality score: R2, D2, W1 = 5/5 Parke-Davis Pfizer sponsored
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Yes	“computer generated code”
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Yes	“identical capsules”